Clinical Trials Logo

Leukemia, Acute clinical trials

View clinical trials related to Leukemia, Acute.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06335277 Recruiting - Lymphoma Clinical Trials

Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology

Start date: February 22, 2018
Phase:
Study type: Observational

Patients eligible undergoing total body irradiation as candidates for bone marrow or peripheral stem cell transplant.

NCT ID: NCT05823571 Recruiting - Multiple Myeloma Clinical Trials

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Start date: July 6, 2023
Phase: Phase 1
Study type: Interventional

This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also known as a 'mini' transplant) to help prevent certain complications such as cytokine release syndrome (CRS) for patients with blood cancers, using peripheral blood from a relative. The investigators will also examine if by using itacitinib the investigators can reduce the duration of MMF (other immune suppressive drug administration posttransplant).

NCT ID: NCT05236296 Recruiting - Leukemia, Acute Clinical Trials

Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) Pilot Study

EASE-CG
Start date: April 12, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to test the feasibility and acceptability of an adapted psychosocial intervention, called Emotion and Symptom-focused Engagement for Caregivers (EASE-CG), to reduce traumatic stress symptoms and other psychological distress and increase well-being in primary caregivers of patients newly diagnosed with acute leukemia.

NCT ID: NCT04482894 Recruiting - Clinical trials for Myelodysplastic Syndromes

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Start date: August 19, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.

NCT ID: NCT03680677 Recruiting - MDS Clinical Trials

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Start date: September 21, 2018
Phase:
Study type: Observational

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

NCT ID: NCT03564704 Recruiting - Leukemia Clinical Trials

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Start date: February 14, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial PDT-ALL-LBL is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide for adult T-ALL/LBL. Compared to PDT-ALL-2016 for B-ALL, HDACi chidamide will be administrated from induction therapy to maintenance therapy, along with higher dose of consolidation regimen of cytarabine, methotrexate, cyclophosphamide.

NCT ID: NCT03564470 Recruiting - Leukemia Clinical Trials

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Start date: February 14, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Ph-like ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, two-arm, multi-site trial PDT-Ph-like-ALL is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide and dasatinib for adult Ph-like ALL.

NCT ID: NCT03553238 Recruiting - Leukemia, Acute Clinical Trials

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Start date: February 14, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

ETP-ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial is aimed to evaluate the safety and effect of a novel oral histone deacetylase inhibitor chidamide for adult ETP-ALL/LBL in CHINA.